Accordingly, we aimed to investigate and explore the possible role of TUG-1/miR-186/SIRT3, PPAR-1α and HIF-1α axis in TMX resistance and TMX sensitive BC patients and to correlate the aforementioned axis with tumor progression, different clinical presentations, anthropometric parameters and other metabolic biomarkers in BC. The gene discussed is HIF1A; the disease is neoplasm.